Aspirin Use in Immune Thrombocytopenia

Introduction to Aspirin Contraindication

Aspirin is generally contraindicated in patients with immune thrombocytopenia (ITP), particularly when platelet counts are below 50,000/μL, due to the significantly increased risk of serious bleeding complications 1

The decision to use aspirin in ITP depends critically on the platelet count, with severe thrombocytopenia (platelets <50,000/μL) being a contraindication due to prohibitively high bleeding risk 1
The American Society of Hematology guidelines emphasize that treatment decisions in ITP should focus on bleeding risk rather than platelet count alone 2
Cessation of drugs reducing platelet function, such as aspirin, is recommended as a general measure to minimize bleeding risk 3

Patients with cardiac stents requiring aspirin and/or clopidogrel may necessitate raising the threshold platelet count for treatment 3
Use of the lowest effective dose (75-100 mg daily) of aspirin is recommended to minimize bleeding risk when aspirin is absolutely required 1

Regular monitoring of platelet counts is essential when aspirin is used in patients with ITP 1
Watching for signs of bleeding, including petechiae, ecchymosis, epistaxis, or gastrointestinal bleeding, is crucial when aspirin is used in ITP patients 1
The American College of Cardiology is not mentioned in this context, however, the general principle of using aspirin with caution applies, and the American Society of Hematology guidelines provide a framework for management 2

Unnecessarily high doses of aspirin should not be used, as this increases bleeding risk without additional antithrombotic benefit 1
ITP management should not be confused with myeloproliferative disorders, where aspirin is routinely recommended despite thrombocytosis 5, 1